Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Trimmer EE, Essigmann JM. Cisplatin. Essays Biochem. 1999;34:191–211.

Article  CAS  PubMed  Google Scholar 

Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88: 102925.

Article  CAS  PubMed  Google Scholar 

Riddell IA. Cisplatin and oxaliplatin: our current understanding of their actions. Met Ions Life Sci. 2018;18:1.

CAS  Google Scholar 

Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010;39:8113–27.

Article  CAS  PubMed  Google Scholar 

Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77:1103–24.

Article  CAS  PubMed  Google Scholar 

Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol. 2020;11:343.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 2011;14:22–34.

Article  CAS  PubMed  Google Scholar 

Kilari D, Guancial E, Kim ES. Role of copper transporters in platinum resistance. World J Clin Oncol. 2016;7:106–13.

Article  PubMed  PubMed Central  Google Scholar 

Bai L, Gao C, Liu Q, Yu C, Zhang Z, Cai L, et al. Research progress in modern structure of platinum complexes. Eur J Med Chem. 2017;140:349–82.

Article  CAS  PubMed  Google Scholar 

Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016;10:1885–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006;70:1390–4.

Article  CAS  PubMed  Google Scholar 

Liu JJ, Lu J, McKeage MJ. Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. Curr Cancer Drug Targets. 2012;12:962–86.

Article  CAS  PubMed  Google Scholar 

Li YQ, Yin JY, Liu ZQ, Li XP. Copper efflux transporters ATP7A and ATP7B: novel biomarkers for platinum drug resistance and targets for therapy. IUBMB Life. 2018;70:183–91.

Article  CAS  PubMed  Google Scholar 

Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10:1429.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018;217:2291–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol. 2019;53:148–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatem E, El Banna N, Huang ME. Multifaceted roles of glutathione and glutathione-based systems in carcinogenesis and anticancer drug resistance. Antioxid Redox Signal. 2017;27:1217–34.

Article  CAS  PubMed  Google Scholar 

Nunes SC, Serpa J. Glutathione in ovarian cancer: a double-edged sword. Int J Mol Sci. 2018;19:1882.

Article  PubMed  PubMed Central  Google Scholar 

Lan D, Wang L, He R, Ma J, Bin Y, Chi X, et al. Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells. Am J Transl Res. 2018;10:1295–309.

CAS  PubMed  PubMed Central  Google Scholar 

Du H, Chen B, Jiao NL, Liu YH, Sun SY, Zhang YW. Elevated glutathione peroxidase 2 expression promotes cisplatin resistance in lung adenocarcinoma. Oxid Med Cell Longev. 2020;2020:7370157.

Article  PubMed  PubMed Central  Google Scholar 

Si M, Lang J. The roles of metallothioneins in carcinogenesis. J Hematol Oncol. 2018;11:107.

Article  PubMed  PubMed Central  Google Scholar 

Merlos Rodrigo MA, Jimenez Jimemez AM, Haddad Y, Bodoor K, Adam P, Krizkova S, et al. Metallothionein isoforms as double agents—their roles in carcinogenesis, cancer progression and chemoresistance. Drug Resist Updat. 2020;52: 100691.

Article  PubMed  Google Scholar 

Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB, Menck CFM. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo). 2018;73:e478s.

Article  PubMed  Google Scholar 

Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14:1291–5.

Article  CAS  PubMed  Google Scholar 

Duan M, Ulibarri J, Liu KJ, Mao P. Role of nucleotide excision repair in cisplatin resistance. Int J Mol Sci. 2020;21:9248.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancers (Basel). 2019;11:119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34:360–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen SH, Chang JY. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 2019;20:4136.

Article  PubMed  PubMed Central  Google Scholar 

Wong-Brown MW, van der Westhuizen A, Bowden NA. Targeting DNA repair in ovarian cancer treatment resistance. Clin Oncol (R Coll Radiol). 2020;32:518–26.

Article  CAS  PubMed  Google Scholar 

Gasiorkiewicz BM, Koczurkiewicz-Adamczyk P, Piska K, Pekala E. Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer. Invest New Drugs. 2021;39:538–63.

Article  CAS  PubMed  Google Scholar 

Haynes B, Saadat N, Myung B, Shekhar MP. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance. Mutat Res Rev Mutat Res. 2015;763:258–66.

Article  CAS  PubMed  Google Scholar 

Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21:37–50.

Article  CAS  PubMed  Google Scholar 

Kopa P, Macieja A, Pastwa E, Majsterek I, Poplawski T. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells. Mol Biol Rep. 2021;48:709–20.

Article  CAS  PubMed  Google Scholar 

Luo Y, Rockow-Magnone SK, Kroeger PE, Frost L, Chen Z, Han EK, et al. Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. Neoplasia. 2001;3:411–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koberle B, Schoch S. Platinum complexes in colorectal cancer and other solid tumors. Cancers (Basel). 2021;13:2073.

Article  PubMed  Google Scholar 

Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC, et al. Autophagy and multidrug resistance in cancer. Chin J Cancer. 2017;36:52.

Article  PubMed